Company Announcement,
Person subject to the notification requirement
Position: Member of the Board/Deputy member
Issuer:
LEI: 743700S7ZI0LNMHZ6Y27
Notification type: INITIAL NOTIFICATION
Reference number: 59511/5/4
____________________________________________
Transaction date: 2024-04-23
Outside a trading venue
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Nature of transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 8500 Unit price:
Aggregated transactions (1):
Volume: 8500 Volume weighted average price:
Further information is available on the website www.nexstim.com, or by contacting:
+358 50 326 4101
mikko.karvinen@nexstim.com
The Company’s Certified Advisor is
About
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in
For more information, please visit www.nexstim.com
Attachment
- Nexstim Plc_Company announcement_Managers transactions Weckroth_25042024_FINAL_EN
© OMX, source